About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Linical Co., Ltd.(2183) Summary

2183
TSE Standard
Linical Co., Ltd.
290
JPY
+15
(+5.45%)
Apr 10, 11:10 am JST
1.97
USD
Apr 9, 10:10 pm EDT
Result
PTS
outside of trading hours
297
Apr 10, 10:06 am JST
Summary Chart Historical News Financial Result
PER
PBR
0.85
Yield
5.52%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:06 am
299 JPY 2.02 USD
Previous Close Apr 9
275 JPY 1.89 USD
High Apr 10, 9:06 am
299 JPY 2.02 USD
Low Apr 10, 9:29 am
286 JPY 1.94 USD
Volume
37,900
Trading Value
0.01B JPY 0.08M USD
VWAP
297.31 JPY 2.03 USD
Minimum Trading Value
29,000 JPY 197 USD
Market Cap
7.17B JPY 0.05B USD
Number of Trades
24
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Mid
1-Year Average
79
1-Year High Apr 15, 2024
673
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 355,000
Mar 28, 2025 5,000 202,000 40.40
Mar 21, 2025 0 229,500
Mar 14, 2025 0 243,700
Mar 7, 2025 0 262,800
Company Profile
Linical Co., Ltd. specializes in contract research for pharmaceutical development, focusing on Phase II and III clinical trials. The company also provides support for pharmaceutical sales.
Sector
Services
Linical Co., Ltd. primarily engages in Contract Research Organization (CRO) services for pharmaceutical development, while also offering post-marketing support services for pharmaceuticals. In its CRO business, the company undertakes various tasks including clinical trial monitoring, quality control, data management, statistical analysis, and medical writing for documents such as clinical trial protocols. Additionally, Linical provides drug discovery support services, offering consulting on development strategy planning, regulatory affairs, and approval applications for biotech venture companies. In its post-marketing support business, Linical handles planning, monitoring, and auditing services. Through these operations, Linical offers comprehensive global services spanning from drug discovery support to clinical development, and post-approval lifecycle management, including post-marketing clinical trials and research.